Reviewer #1:
This paper attempts to explain perinatal risk factors and the associated risk of developing pediatric asthma in the mid-childhood and early teenage years. The authors found that some maternal characteristics such as atopy, BMI, race/ethnicity and demographics such as newborn sex, and birth characteristics such as birthweight, gestational age, and mode of delivery were associated with risks of subsequent asthma development in the pediatric population. The paper then goes on to demonstrate the differences in immune response during the different time frames of pregnancy. Throughout the majority of the pregnancy, fetal hematopoiesis generates mostly lymphoid and erythroid lineages. Towards term, the immune cells are predominantly neutrophils and monocytes. Pre-term is characterized primarily by lymphocytes. It was seen during term deliveries that the myeloid response produces several cytokines that shift CD4+ T- cells away from the Th2 response. Enhanced production of IFN gamma by leukocytes stimulation early in life is associated with reduced susceptibility to infections. However, the author states that these findings do not extend to asthma diagnosis in childhood.
Major comments:
I would have liked the paper to readjust the introduction; a lot of emphasis is placed on IFN/infection/asthma, but after this fact, it seems neglected going forward and the paper explores another topic. Instead, the paper's focus was on determining the biological nature, serologically, with a granulocytic luminal marker (PGLYRP-1) and a membrane-bound marker (sIL6Ra) and its association to pediatric asthma.
The take-home message for the paper - that there appears to be an inverse relationship between serum levels of PGLYRP-1 and overall risk for pediatric asthma - should be explored in relation to the whether a therapeutic role for such proteins is possible since they can accurately predict risk factors for disease and assess pulmonary function. Other proteins, like the sIL6Ra, have no association with disease predictability and have no association with predicting pulmonary outcomes. This should be explored/explained in greater detail.
Minor comments:
As part of the validation efforts of the study - the rationale for using three different cohorts to assess pediatric asthma risk was not clearly explained.
One of the main findings of the analysis was the conclusion that patients with higher levels of myeloid cells in their CBMCs are at lower risk of developing pediatric asthma, and vice versa. Furthermore, CBMC neutrophil abundance was negatively associated with the number of risk factors. (patients with more risk factors, as mentioned above, were found to have lower levels of neutrophils in their CBMC, and more at risk of pediatric asthma). This was further elucidated with measuring CBMC plasma levels of PGLYRP-1 with levels of mRNA and correlating it with risk of developing pediatric asthma. Increased levels of mRNA for the PGLYRP-1 protein was associated with an increased serum concentration of the protein. However, this was inversely correlated with risk factors. Patients with reduced risk factors for development of pediatric asthma were found to have increased levels of the protein and its mRNA.
The measurement and correlation of PGLYRP-1 (present in neutrophil specific granules) and sIL6Ra (derived from neutrophils, but not present in granules) to pediatric asthma at mid-childhood and early-teen years was determined. There were two follow-up points where asthma outcomes and pulmonary function by way of the FEV1/FVC ratio was determined. It was found that increased levels of PGLYRP-1 were significantly associated with current asthma at mid-childhood. However, there was no association between levels at the early-teen follow-up.
In terms of correlations between each protein level and pulmonary function - the sIL6Ra protein was NOT associated with the FEV1/FVC ratio or a bronchodilator response at either age group. However, it was found that increased levels of PGLYRP-1 were associated with an INCREASED FEV1/FVC ratio (not indicative of asthma) and reduced odds of developing pediatric asthma at each age group.
This analysis makes sense as increased production of neutrophil granules, PGLYRP-1, serves a protective effect against infection, reducing incidence of disease states. The paper, however, should explore the rationale behind the no-response to the sIL6Ra protein. In terms of understanding, since this protein is NOT associated with neutrophilic granules, it can be inferred, that is it may not have a role in protecting against infection. However, this could have been explored in more detail in the paper.